ReviewNature reviews. Immunology2021
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
Review in Nature reviews. Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 109 citations in OpenAlex.
- Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population.Viruses · 2022Trial
- Hidden asymptomatic breakthrough infection in a proof-of-concept longitudinal study on SARS-CoV-2 vaccine recipients.Journal of biomedical science · 2026Article
- SCARCE: aSymptomatic respiratory viral Carriage in pre-lung transplant recipients and the effect on eArly-post lung tRansplant CoursE.JHLT open · 2026Article
- Detection of ongoing asymptomaticFrontiers in microbiology · 2026Article
- The seven enigmas of SARS-CoV-2: from the past to the future.Journal of human immunity · 2025Article
- Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice.iScience · 2025Article
- Metabolomics and Cytokine Signatures in COVID-19: Uncovering Immunometabolism in Pathogenesis.Metabolites · 2025Article
- Nanomaterial-Based Biosensors for the Detection of COVID-19.Indian journal of microbiology · 2025Article
- Article
- Analysis on effectiveness of subway epidemic prevention measures considering subway passenger flow.Frontiers in public health · 2025Article
- Validation of Ethical COVID-19 Antibody Testing that Adheres to Pro-Life Principles.The Linacre quarterly · 2024Article
- Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platform.medRxiv : the preprint server for health sciences · 2024Article
- Household Transmission Dynamics of Asymptomatic SARS-CoV-2-Infected Children: A Multinational, Controlled Case-Ascertained Prospective Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Hybrid Immunity Overcomes Defective Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients.Kidney international reports · 2024Article
- Rate and Risk Factors of Reinfection, Recurrence, and Hospital Readmission Among SARS-Cov-2 Hospitalized Patients; a National Cohort Study.Archives of academic emergency medicine · 2024Article
- Prevalence, under-reporting, and epidemiological surveillance of COVID-19 in the Araguaína City of Brazil.PloS one · 2024Article
- Prolonged fecal shedding of replication-competent virus, lasting immune activation, and intestinal inflammation in a rhesus macaque after experimental SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2024Article
- Blood circulating bacterial DNA in hospitalized old COVID-19 patients.Immunity & ageing : I & A · 2023Article
- Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs.Nature communications · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
An important challenge during the COVID-19 pandemic has been to understand asymptomatic disease and the extent to which this may be a source of transmission. As asymptomatic disease is by definition hard to screen for, there is a lack of clarity about this aspect of the COVID-19 spectrum. Studies have considered whether the prevalence of asymptomatic disease is determined by differences in age, demographics, viral load, duration of shedding, and magnitude or durability of immunity. It is clear that adaptive immunity is strongly activated during asymptomatic infection, but some features of the T cell and antibody response may differ from those in symptomatic disease. Areas that need greater clarity include the extent to which asymptomatic disease leads to persistent symptoms (long COVID), and the quality, quantity and durability of immune priming required to confer subsequent protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.